Rapid, Simple and Low-Cost Analytical Method Development for Quantification of Eltrombopag Olamine in Tablet Dosage by UV Spectroscopy Method
- 1 March 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 17 (1) , 42-48
Abstract
Background: Eltrombopag Olamine is a drug used to treat thrombocytopenia, a dis-order where blood platelet counts get lower and severe aplastic anemia. It serves as a thrombo-poietin receptor agonist, which give rise to platelet production in the bone marrow. Objectives: The objective of this study is to develop a simple, specific, accurate, precise and economical Ultraviolet spectroscopy method to estimate the amount of Eltrombopag Olamine in bulk and tablet dosage form. Methods: The developed method was performed using methanol for identification and physico-chemical characterization of the drug. The validation parameters like linearity, precision, accuracy, robustness limits of detection and quantitation, and specificity were assessed as per ICH Q2 (R2). Results: The maximum absorbance wavelength (λmax) of the drug was found at 247 nm in methanol. The linearity was found in the concentration range of 2-14 μg/ml with regression equation y = 0.0619x - 0.0123 and r² = 0.999. The standard addition method was used to deter-mine the accuracy of the developed method. The result was found in the % recovery range of 98-99%. The precision was done on λmax with respect to the parameters such as repeatability, intraday, and interday. The method was found to be precise as the % RSD value was found to be <2%. The detection limit value (LOD) and quantitation limit value (LOQ) were 0.0524 μg/ml and 0.1588 μg/ml, respectively. Conclusion: The developed method is simple, economical, accurate and selective. The developed method was adaptable for the estimation of Eltrombopag Olamine analysis in pharmaceutical dosage form and routine quality control laboratory.Keywords
This publication has 20 references indexed in Scilit:
- Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real‐World Pharmacovigilance and Randomized Clinical TrialsClinical Pharmacology & Therapeutics, 2023
- Stability-Indicating RP-HPLC Method Development and Validation for Eltrombopag Olamine in the Presence of Impurities and Degradation Products. Robustness by Design of Expert SoftwareJournal of AOAC INTERNATIONAL, 2022
- QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity predictionJournal of Pharmaceutical and Biomedical Analysis, 2021
- Analytical techniques in pharmaceutical analysis: A reviewArabian Journal of Chemistry, 2017
- Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 yearsAmerican Journal of Hematology, 2016
- Pathophysiology and management of primary immune thrombocytopeniaInternational Journal of Hematology, 2013
- Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profileTherapeutic Advances in Hematology, 2012
- Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human SubjectsDrug Metabolism and Disposition, 2011
- Pharmacokinetics and Hepatic Uptake of Eltrombopag, a Novel Platelet-Increasing AgentDrug Metabolism and Disposition, 2011
- Key aspects of analytical method validation and linearity evaluationJournal of Chromatography B, 2009